Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Compass Therapeutics, Inc. (CMPX) Tops Q1 EPS by 3c
May 13, 2024 8:02 AM EDTCompass Therapeutics, Inc. (NASDAQ: CMPX) reported Q1 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11).
For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.
... More